Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 14th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.05). Foamix Pharmaceuticals had a negative net margin of 823.74% and a negative return on equity of 39.20%. The firm had revenue of $0.80 million during the quarter, compared to analyst estimates of $1.50 million. During the same period in the prior year, the business earned ($0.27) EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, analysts expect Foamix Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of Foamix Pharmaceuticals Ltd. (NASDAQ FOMX) opened at $6.10 on Tuesday. Foamix Pharmaceuticals Ltd. has a 12 month low of $4.03 and a 12 month high of $11.27.

TRADEMARK VIOLATION NOTICE: “Foamix Pharmaceuticals Ltd. (FOMX) Scheduled to Post Quarterly Earnings on Tuesday” was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/foamix-pharmaceuticals-ltd-fomx-scheduled-to-post-quarterly-earnings-on-tuesday/1684222.html.

Several analysts have issued reports on FOMX shares. Zacks Investment Research downgraded Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. HC Wainwright assumed coverage on Foamix Pharmaceuticals in a research note on Thursday, August 24th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Credit Suisse Group reaffirmed a “buy” rating and issued a $9.00 target price on shares of Foamix Pharmaceuticals in a research report on Wednesday, July 19th.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.